# Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

> **NCT01602406** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Advanced HER2-positive Breast Cancer or Gastric Cancer

## Interventions

- **DRUG:** LJM716
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01602406
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-21
- **Primary completion:** 2017-08-02
- **Final completion:** 2017-08-02
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01602406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01602406, "Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01602406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*